Sonia Seng, MD
Hematology & Oncology · Fall River, MANPI 1366629719
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $181 of the $262 with a category attached, or 69.0%. 5 manufacturers reported payments, led by Bristol Myers Squibb at 50.1% of the total. Reporting peaked in 2023 at $131 and has fallen 82.9% since, to $22 in 2024. That places this record below the midpoint for hematology & oncology clinicians in MA, where the typical reported total is $856.
Across 10 payments — averaging $26.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$131
- E.r. Squibb & Sons, L.L.C.$45
- GSK$36
- Genentech USA, Inc.$27
- AstraZeneca$22
Across 268 payments — averaging $4729.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$373K
- Seagen Inc.$242K
- AstraZeneca$187K
- Genentech, Inc.$135K
- Eli Lilly$131K
- F. Hoffmann-la Roche AG$124K
- plus $75K from 3 others
What the payments were for
- Food & beverage$18169%
- Education$8131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 5 | $131 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| GSK | 1 | $36 |
| Genentech USA, Inc. | 1 | $27 |
| AstraZeneca | 1 | $22 |
How this compares
$262 in reported general payments places this provider in the 35th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 12 | $116,679 |
| TafinlarDabrafenib Mesylate | 12 | $89,373 |
| Abiraterone Acetate | 37 | $61,369 |
| EliquisApixaban | 74 | $50,854 |
| Imatinib Mesylate | 12 | $33,572 |
| XareltoRivaroxaban | 32 | $28,764 |
| Tamoxifen Citrate | 93 | $2,451 |
| Letrozole | 92 | $1,788 |
| Prochlorperazine Maleate | 39 | $821 |
| Dexamethasone | 50 | $646 |
| Anastrozole | 22 | $598 |
| Oxycodone Hcl | 45 | $579 |
| Gabapentin | 40 | $483 |
| Ondansetron Hcl | 29 | $371 |
| Allopurinol | 47 | $274 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Fall River
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Stephanie BernsteinWinchester$622K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Karl DsilvaPeabody$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.